Cargando…
Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer’s disease
BACKGROUND: PET radiopharmaceuticals capable of imaging β-amyloid (Aβ) plaque burden in the brain could offer highly valuable diagnostic tools for clinical studies of Alzheimer’s disease. To further supplement existing armamentarium of FDA-approved agents as well as those under development, and to c...
Autores principales: | Sundaram, Guruswami SM, Dhavale, Dhruva, Prior, Julie L, Sivapackiam, Jothilingam, Laforest, Richard, Kotzbauer, Paul, Sharma, Vijay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478171/ https://www.ncbi.nlm.nih.gov/pubmed/26061601 http://dx.doi.org/10.1186/s13550-015-0112-4 |
Ejemplares similares
-
Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer’s Disease
por: Sundaram, G. S. M., et al.
Publicado: (2016) -
PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity
por: Sivapackiam, Jothilingam, et al.
Publicado: (2020) -
A Generator-Produced Gallium-68 Radiopharmaceutical for PET Imaging of Myocardial Perfusion
por: Sharma, Vijay, et al.
Publicado: (2014) -
(68)Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity
por: Sivapackiam, Jothilingam, et al.
Publicado: (2019) -
Galuminox: Preclinical validation of a novel PET tracer for non-invasive imaging of oxidative stress in vivo
por: Sivapackiam, Jothilingam, et al.
Publicado: (2020)